Research
Lactobacillus casei
37 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 18 studies (14 RCTs and 4 prospective trials) on nonintravesical interventions for NMIBC. Lactobacillus casei significantly improved intravesical recurrence-free survival, while a high western diet pattern worsened it. Other interventions showed no significant association with iRFS.
Lactobacillus casei Alleviated the Abnormal Increase of Cholestasis-Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial.
Post hoc analysis of an RCT with 429 patients receiving standard tuberculosis therapy alone or with Lactobacillus casei. L. casei supplementation significantly reduced the incidence of abnormal increases in cholestasis-related liver indices and altered gut microbiota composition.
Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis.
Systematic review and network meta-analysis of 10 RCTs with 4,692 patients evaluating probiotics for preventing Clostridium difficile-associated diarrhea (CDAD). Probiotic interventions, particularly Lactobacillus casei, significantly reduced the incidence rates of CDAD and antibiotic-associated diarrhea (AAD) compared to placebo.
Do probiotics prevent antibiotic-associated diarrhoea? Results of a multicentre randomized placebo-controlled trial.
A multicentre, double-blind, placebo-controlled, randomized trial evaluated Lactobacillus casei DN114001 in reducing antibiotic-associated diarrhoea (AAD) and Clostridioides difficile infection in patients over 55 years. No significant evidence was found of a beneficial effect of the probiotic in preventing AAD.
Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial.
Randomized, open-label, dose-response trial investigating the effects of Lactobacillus casei on anti-TB-induced gastrointestinal adverse events in 429 adult patients. Both high and low dose L. casei groups showed lower incidences and shorter durations of gastrointestinal symptoms compared to the control group, indicating preventive effects.
Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial.
RCT involving 1072 elderly participants comparing a fermented dairy product containing Lactobacillus casei DN-114 001 to a control dairy product. The fermented product significantly reduced the duration of common infectious diseases, particularly upper respiratory tract infections, compared to the control.
The effect of probiotic supplementation on episiotomy wound healing among primiparous women: a triple-blind randomized clinical trial.
This triple-blind randomized clinical trial evaluated the effect of Lactobacillus casei oral supplementation on episiotomy wound healing among 74 primiparous women. The probiotic group showed significant improvement in wound healing scores compared to the placebo group over 15 days.
Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.
Double-blind randomized controlled trial of 158 patients with alcoholic liver injury, testing low and high doses of Lactobacillus casei strain Shirota. The high-dose group showed significant decreases in serum TG and LDLC levels and increased amounts of Lactobacillus and Bifidobacterium compared to the control group.
The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study.
Phase IV study evaluating Lactobacillus casei DG® in patients with chronic bacterial prostatitis. The treatment improved clinical symptoms, reduced symptomatic recurrences, and decreased antibiotic use, with significant changes in NIH-CPSI, IPSS, and QoL scores.
Fermented Milk Consumption and Common Infections in Children Attending Day-Care Centers: A Randomized Trial.
This multicenter, double-blind, randomized, placebo-controlled trial investigated the effect of a fermented milk product containing Lactobacillus casei on common infectious diseases in children attending day-care centers. No significant difference in overall incidence of infections was found between groups, but a lower incidence of rhinopharyngitis was observed in the fermented milk group.
Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.
A prospective, randomized, controlled trial evaluated the effect of oral Lactobacillus casei on recurrence prevention in bladder cancer patients receiving epirubicin. The 3-year recurrence-free survival rate was significantly higher in the group receiving both epirubicin and Lactobacillus casei compared to epirubicin alone.
Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors.
RCT of 398 subjects examining the effects of dietary fiber and Lactobacillus casei on colorectal tumor prevention. No significant difference in new tumor development was observed, but L. casei administration was associated with a lower occurrence rate of tumors with moderate atypia or higher.
Lactobacillus casei modulates inflammatory cytokines and metabolites during tuberculosis treatment: A post hoc randomized controlled trial.
A randomized controlled trial with 47 inpatients investigated the effects of Lactobacillus casei on inflammatory cytokines and metabolites during tuberculosis treatment. Lactobacillus casei supplementation significantly lowered inflammatory cytokines and modulated plasma metabolites, suggesting beneficial effects during tuberculosis treatment.
Effect of probiotic bacteria in composition of children's saliva.
The study evaluated the effect of petit-suisse cheese plus probiotic Lactobacillus casei on the microbiota of children's saliva. The probiotic product significantly reduced the total number of microorganisms and Streptococcus mutans, and decreased the density of Agreggatibacter actinomycetemcomitans, while maintaining low density of Porphyromonas gingivalis post treatment.
Effects of using symbiotics in the clinical nutritional evolution of patients with chronic pancreatitis: Study prospective, randomized, controlled, double blind.
Prospective, randomized, controlled, double-blind study assessing the effects of symbiotics on patients with chronic pancreatitis. The intervention group showed significant improvements in clinical and laboratory profiles, including increased hemoglobin, hematocrit, red blood cells, total lymphocyte count, serum magnesium, and albumin, as well as reduced total serum cholesterol.
Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia.
A randomized controlled trial was conducted with 150 adult patients to evaluate the efficacy of probiotics containing Lactobacillus casei (Shirota strain) in reducing the incidence of ventilator-associated pneumonia (VAP). The probiotics group showed a tendency to reduce VAP incidence and colonization with resistant bacteria, though differences in mortality and hospital stay were not significant.
Synbiotic in the management of infantile colic: a randomised controlled trial.
RCT of 50 breastfed infants with infantile colic comparing synbiotic sachet to placebo for 30 days. The synbiotic group showed significantly higher treatment success in reducing daily crying time compared to placebo at both day 7 and day 30.
Influence of a probiotic Lactobacillus casei strain on the colonisation with potential pathogenic streptococci and Staphylococcus aureus in the nasopharyngeal space of healthy men with a low baseline NK cell activity.
RCT investigating the effect of Lactobacillus casei Shirota on nasopharyngeal colonisation with potential pathogens in healthy men with low NK cell activity. The probiotic did not significantly affect colonisation by Staphylococcus aureus or streptococci, nor did it influence salivary SIgA production.
The effect of Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea treatment: randomized double-blind clinical trial.
RCT investigating the effect of probiotics Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea in hospitalized patients. The study found no significant effect of the probiotics on the duration or cure rate of diarrhea compared to placebo.
Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial.
RCT of 85 patients undergoing pelvic radiotherapy for gynecologic cancer, comparing a probiotic drink containing Lactobacillus casei DN-114 001 to placebo. The probiotic did not reduce the incidence of radiation-induced diarrhea but significantly affected stool consistency.
Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon.
Prospective dose-finding study on 75 patients with symptomatic diverticular disease, testing mesalazine and/or Lactobacillus casei. After 24 months, 88% of patients were symptom-free, with varying success rates across different treatment groups. Recurrence and complications occurred in patients who suspended treatment.
A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis.
RCT of 187 preschool children with allergic asthma and/or rhinitis comparing long-term consumption of fermented milk containing Lactobacillus casei to placebo. No effect was found in asthmatic children, but children with rhinitis had fewer episodes and shorter duration of diarrhea.
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.
Prospective, randomized, open-label study of 90 patients with symptomatic uncomplicated diverticular disease of the colon. Patients were assigned to mesalazine, Lactobacillus casei, or a combination for 12 months. The combination group showed the highest symptom-free rate, suggesting the combination is more effective in preventing recurrence.
A new synbiotic, Lactobacillus casei subsp. casei together with dextran, reduces murine and human allergic reaction.
The study investigated the effects of a synbiotic combination of Lactobacillus casei subsp. casei and dextran on allergic reactions in NC/Nga mice and healthy volunteers during the cedar pollen season in Japan. In mice, the synbiotic significantly decreased clinical skin severity scores and total immunoglobulin E levels. In humans, the synbiotic led to no significant changes in allergy symptoms or immune markers, while the placebo group showed a tendency for increased allergy markers.
Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children.
Double-blind trial with 89 children aged 6-24 months to evaluate the effect of Lactobacillus casei, Lactobacillus acidophillus, and Saccharomyces boulardii on persistent diarrhea. Both probiotics significantly reduced the number of depositions, diarrheal duration, and vomiting compared to placebo.
Childhood allergy is preceded by an absence of gut lactobacilli species and higher levels of atopy-related plasma chemokines.
The study investigated the association between gut lactobacilli and allergy development in 194 children followed from infancy to 10 years of age. An absence of lactobacilli and higher levels of atopy-related chemokines in infancy were linked to allergy development, suggesting that certain lactobacilli species may contribute to allergy protection.
The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
RCT of 40 patients with T2DM comparing Lactobacillus casei supplementation to placebo for eight weeks. The probiotic group showed significant decreases in fasting blood sugar, insulin concentration, and insulin resistance, and significant changes in SIRT1 and fetuin-A levels, suggesting improved glycemic response.
The Influence of Probiotic Lactobacillus casei in Combination with Prebiotic Inulin on the Antioxidant Capacity of Human Plasma
RCT assessing the influence of synbiotics containing Lactobacillus casei and Inulin on antioxidant properties of human plasma in 32 healthy volunteers. The synbiotic group showed a significant increase in FRAP values and CAT activity, suggesting a positive influence on plasma antioxidant capacity.
Effects of Probiotic Supplementation on Oxidative Stress Indices in Women with Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial.
RCT of 46 women with rheumatoid arthritis evaluating the effects of Lactobacillus casei 01 supplementation on oxidative stress indices. No significant effect was observed on oxidative status compared to placebo.
Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial.
This randomized double-blind clinical trial investigated the effects of Lactobacillus casei 01 supplementation on rheumatoid arthritis symptoms and inflammatory biomarkers in women. The probiotic group showed decreased serum hs-CRP levels, tender and swollen joint counts, global health score, and DAS28. Significant differences in IL-10, IL-12, and TNF-α changes favored the probiotic group, suggesting it may be an effective adjunct therapy for RA.
Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study.
RCT evaluating the effect of Lactobacillus casei on small bowel injuries in chronic low-dose aspirin users. Significant decreases in mucosal breaks and CE scores were observed in the L. casei group compared to the control group, indicating positive effects on gut health.
Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.
RCT involving 26 patients with mild ulcerative colitis, comparing the effects of 5-ASA alone, 5-ASA with oral L. casei DG, and 5-ASA with rectal L. casei DG. Rectal administration of L. casei DG modified colonic microbiota and reduced TLR-4 and IL-1β mRNA levels while increasing mucosal IL-10, suggesting beneficial effects on gut health and inflammation.
Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Its effect on tumor reduction and histology.
RCT of 61 patients with carcinoma of the uterine cervix studying the combination of LC9018, a biological response modifier from heat-killed Lactobacillus casei, with radiation therapy. The combination therapy showed significant tumor reduction and protection from leukopenia compared to radiation alone.
Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis.
RCT comparing different lactic acid bacteria on immune response to rotavirus in 49 children with acute rotavirus gastroenteritis. LGG therapy enhanced IgA sASC to rotavirus and serum IgA antibody levels, suggesting certain strains promote immune responses to rotavirus.
Oral bacteriotherapy for viral gastroenteritis.
RCT testing the effect of orally administered Lactobacillus casei strain GG on acute rotavirus diarrhea in 42 well-nourished children. The study group receiving lactobacilli showed a shortened diarrheal phase and a significant influence on bacterial enzyme profile compared to the control group.
Probiotics and Amelioration of Rheumatoid Arthritis: Significant Roles of Lactobacillus casei and Lactobacillus acidophilus
Narrative review recapitulating recent studies on the pathogenesis of rheumatoid arthritis and the roles of probiotics, particularly Lactobacillus casei and Lactobacillus acidophilus, in managing rheumatoid arthritis in clinical and preclinical studies.
The effects of the Lactobacillus casei strain on obesity in children: a pilot study.
Pilot study examining the effects of Lactobacillus casei strain Shirota (LcS) on obesity in children. The study found significant weight loss and improved lipid metabolism in obese children after 6 months of LcS beverage ingestion, with increased faecal Bifidobacterium numbers and acetic acid concentration.